Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) Other Non Operating Income (2016 - 2025)

Historic Other Non Operating Income for Amicus Therapeutics (FOLD) over the last 17 years, with Q3 2025 value amounting to $10.9 million.

  • Amicus Therapeutics' Other Non Operating Income rose 43365.0% to $10.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.0 million, marking a year-over-year increase of 20089.04%. This contributed to the annual value of -$9.4 million for FY2024, which is 4057.03% up from last year.
  • Per Amicus Therapeutics' latest filing, its Other Non Operating Income stood at $10.9 million for Q3 2025, which was up 43365.0% from $1.0 million recorded in Q2 2025.
  • Amicus Therapeutics' Other Non Operating Income's 5-year high stood at $13.6 million during Q3 2022, with a 5-year trough of -$18.6 million in Q4 2022.
  • Moreover, its 5-year median value for Other Non Operating Income was -$172000.0 (2021), whereas its average is -$636526.3.
  • Within the past 5 years, the most significant YoY rise in Amicus Therapeutics' Other Non Operating Income was 540505.84% (2022), while the steepest drop was 1073023.26% (2022).
  • Amicus Therapeutics' Other Non Operating Income (Quarter) stood at -$172000.0 in 2021, then crashed by 10730.23% to -$18.6 million in 2022, then skyrocketed by 84.54% to -$2.9 million in 2023, then soared by 187.01% to $2.5 million in 2024, then soared by 334.61% to $10.9 million in 2025.
  • Its last three reported values are $10.9 million in Q3 2025, $1.0 million for Q2 2025, and $550000.0 during Q1 2025.